Second primary cancer following Hodgkin's disease: Updated results of an Italian multicentric study

Journal Article · Fri Mar 01 04:00:00 EST 1991 · Journal of Clinical Oncology; (USA)

OSTI ID:5952633

Cimino, G; Papa, G; Tura, S; Mazza, P; Rossi Ferrini, P L; Bosi, A; Amadori, S; Lo Coco, F; D'Arcangelo, E; Giannarelli, D ^[1]

---

1. Univ. La Sapienza, Rome (Italy)

The risk of second primary cancer (SPC) was evaluated in 947 patients treated for Hodgkin's disease (HD) during the period January 1969 to December 1979. The median follow-up of this series was 10.5 years (range, 9 to 19). Treatment categories included radiotherapy (RT) alone (115 patients, 12%), chemotherapy (CHT) alone (161 patients, 17%), combined RT plus CHT (381 patients, 40%), and salvage treatment for resistant or relapsing HD (290 patients, 30.6%). Fifty-six SPCs were observed, occurring between 1 and 17 years from initial treatment. Among these, secondary acute nonlymphoid leukemia (s-ANLL) was the most frequent SPC (23 cases). Secondary non-Hodgkin's lymphoma (s-NHL) occurred in 5 patients, whereas a secondary solid tumor (s-ST) was observed in 28 patients. The calculated actuarial risk (+/- SE) of developing SPC was 5.0% (+/- 0.9%) and 23.1% (+/- 5.8%) at 10 and 19 years, respectively. Concerning treatment modalities and s-ANLL risk, no cases were observed in the radiotherapy group, whereas CHT plus RT and salvage groups showed the highest actuarial risk. This was, in fact, at 10 and 19 years, 3.1% (+/- 0.9%) and 8.1% (+/- 4.0%) in the former group, and 1.8% (+/- 1.0%) and 16% (+/- 9.0%) in the latter. A statistically significant difference was observed when the CHT plus RT group was compared with CHT and RT groups (P = .04). Concerning the relationships with chemotherapeutic regimens, 12 s-ANLL cases occurred in the mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) plus RT group, and only one case in the group receiving doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) plus RT. A statistically significant difference of s-ANLL actuarial risk was found comparing patients receiving MOPP plus RT to all other treatment groups (P = .04).

• OSTI ID: 5952633
• Journal Information: Journal of Clinical Oncology; (USA), Journal Name: Journal of Clinical Oncology; (USA) Vol. 9:3; ISSN JCOND; ISSN 0732-183X
• Country of Publication: United States
• Language: English

Related Subjects

560151* -- Radiation Effects on Animals-- Man
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
BIOLOGICAL EFFECTS
BIOLOGICAL RADIATION EFFECTS
CHEMOTHERAPY
DELAYED RADIATION EFFECTS
DISEASES
HODGKINS DISEASE
IMMUNE SYSTEM DISEASES
LYMPHOMAS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
PATIENTS
RADIATION EFFECTS
RADIOINDUCTION
RADIOLOGY
RADIOTHERAPY
RISK ASSESSMENT
SIDE EFFECTS
THERAPY